← All indications
Thyroid Carcinoma, Anaplastic
An aggressive THYROID GLAND malignancy which generally occurs in IODINE-deficient areas in people with previous thyroid pathology such as GOITER. It is associated with CELL DEDIFFERENTIATION of THYROID CARCINOMA (e.g., FOLLICULAR THYROID CARCINOMA; PAPILLARY THYROID CANCER). Typical initial presentation is a rapidly growing neck mass which upon metastasis is associated with DYSPHAGIA; NECK PAIN; bone pain; DYSPNEA; and NEUROLOGIC DEFICITS.
Drugs by status
Phase 3 trials (6)
Phase 2 trials (21)
Phase 1 trials (7)
Other trials (1)
Organizations
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (27)
- Daiichi Sankyo
- Eisai
- Millennium Pharmaceuticals
- Roche
- Merck
- Genentech
- Ipsen
- Novartis
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- Region Skane
- Case Western Reserve University
- Harvard University
- Grupo Espanol de Tumores Neuroendocrinos (GETNE)
- Lund University
- NRG Oncology
- Ohio State University
- Stanford University
- Translational Research Informatics Center, Kobe, Hyogo, Japan
- Mayo Clinic
- Fujian Medical University
- Nippon Medical School
- University of Texas at Houston
- Memorial Sloan-Kettering Cancer Center
- The University of Texas, Dallas
- Taizhou Hanzhong biomedical co. LTD
- Vall d'Hebron Institute of Research, Galatea Clinic
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (1)